ClinicalTrials.gg
CompletedNCT01618825Updated Jun 13, 2012

Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fed Condition

A Phase 1 interventional study of Lamotrigine Tablets 25 mg and Lamotrigine in Fed, sponsored by IPCA Laboratories Ltd.. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-13.

Sponsored by IPCA Laboratories Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is an open Label, randomized, two-period, two-treatment, two-sequence, crossover, balanced, single dose pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fed condition in healthy adult human subjects.

Read the detailed description

Objective of this pivotal study was to assess the bioequivalence between Test Product: Lamotrigine Tablets 25 mg (2 x 25 mg)of M/s Ipca Laboratories Limited, India and the corresponding Reference Product: LAMICTAL® (Lamotrigine) Tablets 25 mg (2 x 25 mg) of GlaxoSmithkline, USA, under fed condition in healthy adult human subjects in a randomized crossover study.

The study was conducted with 28 healthy adult subjects. In each study period, a single 2 X 25 mg dose of either test or reference was administered to the subjects as per the randomization schedule in each study period with about 240 mL of water at ambient temperature in sitting position.

The duration of the clinical phase was approximately 26 days including washout period of at least 21 days between administrations of study drug in each study period.

02

Conditions studied

  • Fed
03

In context

Lead sponsor

IPCA Laboratories Ltd. is the lead sponsor of 30 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 to 45 years old, both inclusive.
  2. Sex: Males and/or non-pregnant, non-lactating females.

    A. Females of must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test performed within 21 days prior to initiation of the study \& prior to check-in of each period. They must be using an acceptable form of .

    B. Acceptable forms of contraception include the following:

    i. Intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or

    ii. Barrier methods containing or used in conjunction with a spermicidal agent, or

    iii. Surgical sterilization or

    iv. Practicing sexual abstinence throughout the course of the study.

    C. Females will not be considered of childbearing potential if one one of the following is reported and documented on the medical history:

    i. with spontaneous amenorrhea for at least one year, or

    ii. Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or

    iii. Total hysterectomy and an absence of bleeding for at least 3 months.

  3. : 18.5 to 24.9 weight in Kg / (height in meter)2 both inclusive; BMI value should be rounded off to one significant digit after decimal point (e.g. 24.94 rounds down to 24.9. while 18.45 rounds up to 18.5).
  4. Able to communicate effectively with study personnel and willingness to follow the protocol requirements as evidenced by written .
  5. Able to give written informed consent to participate in the study.
  6. All volunteers must be judged by the principal or co-investigator or physician as normal and healthy during pre-study safety assessment performed within 21 days of the first dose of study medication which will include:

    1. A physical examination with no finding.
    2. Results within normal limits or clinically non-significant for the tests mentioned in list of Laboratory Parameters:

      • Additional tests and/or examinations may be performed, if necessary, based on Principal Investigator discretion.
      • All results will be assessed against the laboratory normal ranges current at the time of testing and a copy of the normal ranges used will be included in the study documentation.

Exclusion criteria

Exclusion Criteria:

  1. History of allergic responses to Lamotrigine or other related drugs, or any of its formulation ingredients.
  2. Have significant diseases or abnormal findings during screening, [medical history, physical examination, laboratory evaluations, , chest X-ray recording, obstetrics and gynecological history and examination along with PAP smear (for female volunteers) \& transvaginal ultrasonography (for female volunteers)].
  3. Any disease or condition which might compromise the haemopoeitic gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system, diabetes, psychosis or any other body system.
  4. History or presence of bronchial asthma.
  5. Use of any hormone replacement therapy within 3 months prior to study medication dosing.
  6. A depot injection or implant of any drug within 3 months prior to administration of study medication.
  7. Use of enzyme-modifying drugs within 30 days prior to receiving the first dose of study medication.
  8. History or evidence of drug dependence or of alcoholism or of moderate alcohol use.
  9. Smokers who smoke 10 or more cigarettes per day or 20 or more biddies per day or those who cannot refrain from smoking during the study period.
  10. History of difficulty with donating blood or difficulty in accessibility of veins.
  11. History of allergic response to heparin.
  12. A positive hepatitis screen (includes subtypes B \& C).
  13. A positive test result for antibody and / or syphilis (RPR/VDRL).
  14. Volunteers who have donated blood (1 unit or 450 ml) within 90 days prior to the initial dose of the study drug or have blood loss, excluding volume drawn at screening for this study drug.
  15. History of difficulty in swallowing, or of any gastrointestinal disease which could affect drug absorption.
  16. Intolerance to venipuncture.
  17. Any food allergy, intolerance, restriction or special diet that, in the opinion of the Principal Investigator, could contraindicate the volunteer's participation in this study.
  18. Volunteers who have received a known drug within five elimination half life of the administered drug prior to the initial dose of study drug or who have participated in a clinical drug study or bioequivalence study within 90 days prior to initial dose of study drug, whichever is greater.
  19. Found positive in urine test for drugs of abuse done before check-in of period I.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Active comparator
    LAMICTAL®

    Lamictal® (Lamotrigine) Tablets 25 mg of GlaxoSmithkline, USA

    Drug: Lamotrigine

  • Experimental
    Lamotrigine Tablets 25 mg

    Lamotrigine Tablets 25 mg of M/s Ipca Laboratories Limited, India

    Drug: Lamotrigine Tablets 25 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence is based on Cmax and AUC parameters.

    Area Under Curve (AUC)and Cmax Sampling Hours: Pre-dose and at 00.50, 01.00, 01.50, 02.00, 02.25, 02.50, 03.00, 03.25, 03.50, 04.00, 04.25, 04.50, 05.00, 05.50, 06.00, 07.00, 08.00, 10.00, 12.00, 14.00, 18.00, 24.00, 36.00, 48.00 and 72.00 hours post-dose.

    Time frame: 3 months

07

Study locations

1 site
  • Cliantha Research Limited
    Ahmedabad, Gujarat, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2012
First posted
Jun 13, 2012
Start
Mar 2012
Primary completionActual
May 2012
CompletionActual
May 2012
Last update
Jun 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01618825
Responsible party
Sponsor
First posted
Jun 13, 2012
Start date
Mar 2012
Primary completion
May 2012
Completion
May 2012
Last update
Jun 13, 2012

Study contacts

Dr. Manish Singhal, MBBS
principal investigator · Cliantha Research Limited

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion